• Globe Newswire

Boehringer’s new zongertinib data demonstrate durable and clinically meaningful results in patients with HER2 (ERBB2)-mutant advanced NSCLC

Globenewswire -

• Globe Newswire

Boehringer Ingelheim and Tessellate Bio partner to develop first-in-class precision treatments for people with hard-to-treat cancers

Globenewswire -

• Globe Newswire

Boehringer Ingelheim strengthens antibody-drug conjugate portfolio with new NBE Therapeutics R&D center in Basel

Globenewswire -

• Globe Newswire

Boehringer Ingelheim expands cancer research at its Vienna site